3rd Edition Speakers

Dr. Matthias Essenpreis

Dr. Matthias Essenpreis

Chief Technology Officer | Roche Diagnostics (Basel, Switzerland)

Keynote speaker

Abstract

PoC Diagnostics has become key for many patients way to manage their disease. For example, using glucose monitoring in the management of their diabetes or coagulation monitoring to adjust anti-coagulation therapy has become routine for patients and physicians. Historically developed as laboratory tests, the transfer of these solutions into the hands of patients has resulted in improved care and allowed flexible life styles whilst managing the disease.

We are currently seeing the emergence of new solutions for disease management from sensor technologies built into smart phones or wearable devices, many of which will eventually find their way into routing therapy. Combining such approaches with IVD based solutions will create opportunities to improve therapy whilst anchoring decision making in today’s standards of care. Evidence for these new solutions is still scare. However, many approaches are being explored and are already seen to educate patients in their therapy. To find full acceptance, such solutions need to demonstrate clinical safety and efficacy as part of modified treatment protocols. In addition, a seamless integration onto physician’s workflow is required to support broad acceptance and support as part of a therapy. This talk will discuss examples of digitally enabled and patient centric tools and provide a perspective of future developments.

Biography

Matthias joined Roche Diagnostics in 1993 and has held various positions in technology assessment, research and product development. In his current role as Chief Technology Officer, he leads a small team to assess platform technologies for future diagnostics products and provides input for business and strategy planning with insights on technology roadmaps. Previously, he has been responsible for new technology development and innovation within Roche Diabetes Care. Besides new technology platforms for next generation test strips, continuous glucose sensors, minituarized insulin pumps, all of which are currently in product development, he has piloted novel information management solutions for the management of T1 and T2 diabetes. His passion of data driven solutions and business models originated during his time in the US Chief Technology Office (Pleasanton) around the year 2000, where he closely followed the emergence of internet businesses. Matthias holds a PhD in Medical Physics from University College London, U.K. and received his M.Sc. Degree in Physics from Ludwig Maximilians Universität in Munich, Germany. Besides his professional passion for business strategy and innovation management he is very motivated to find better products and solutions for patients and improved outcomes. Outdoor sports (hiking and skiing), art (music, modern and asian art) and cooking are some of his private passions.

 

Dr. Jonathan S. Gootenberg

Dr. Jonathan S. Gootenberg

Fellow at Massachusetts Institute of Technology (MIT) and co-founder of Sherlock Biosciences

Keynote speaker

Abstract

RNA plays important and diverse roles in biology, but molecular tools to manipulate and measure RNA are limited. We demonstrate that RNA-targeting CRISPR effector Cas13 can be engineered for RNA diagnostics and mammalian cell RNA knockdown, binding, and editing. We demonstrate diagnostic applications of Cas13 for rapid and sensitive COVID-19 diagnostics. We also show Cas13 can be heterologously expressed in mammalian and plant cells for targeted knockdown of either reporter or endogenous transcripts, targeted RNA binding for transcript imaging, and programmable RNA editing. We develop engineered Cas13-based RNA editing tools for A-to-I and C-to-U base editing and show applications of these tools for therapeutics. Our results establish CRISPR-Cas13 as a flexible platform for RNA targeting with wide applicability for studying RNA or therapeutics.

Dr. Omar O. Abudayyeh

Dr. Omar O. Abudayyeh

Fellow at Massachusetts Institute of Technology (MIT) and co-founder of Sherlock Biosciences

Keynote speaker

Abstract

RNA plays important and diverse roles in biology, but molecular tools to manipulate and measure RNA are limited. We demonstrate that RNA-targeting CRISPR effector Cas13 can be engineered for RNA diagnostics and mammalian cell RNA knockdown, binding, and editing. We demonstrate diagnostic applications of Cas13 for rapid and sensitive COVID-19 diagnostics. We also show Cas13 can be heterologously expressed in mammalian and plant cells for targeted knockdown of either reporter or endogenous transcripts, targeted RNA binding for transcript imaging, and programmable RNA editing. We develop engineered Cas13-based RNA editing tools for A-to-I and C-to-U base editing and show applications of these tools for therapeutics. Our results establish CRISPR-Cas13 as a flexible platform for RNA targeting with wide applicability for studying RNA or therapeutics.

Dr. Michel Rossier

Dr. Michel Rossier

Head of laboratories and Board member of Institut Central des Hôpitaux (Sion, Switzerland)

 

Dr. Sabine Blum

Dr. Sabine Blum

Associate Doctor - Hematologist | CHUV (Lausanne, Switzerland)

 

Dr. Kavi Ramjeet

Dr. Kavi Ramjeet

Technology Scouting Lead | FIND (Geneva, Switzerland)

 

Dr. Mathias Wipf

Dr. Mathias Wipf

Chief Executive Officer and Co-Founder | MOMM Diagnostics (Basel, Switzerland)

 

Dr. Eberhard Scheuer

Dr. Eberhard Scheuer

Founder | Centiva Health (Zug, Switzerland)

 

Dr. Christian-Benedikt Gerhold

Dr. Christian-Benedikt Gerhold

Head Corporate Research| Bühlmann Laboratories AG (Schönenbuch, CH)

 

Dr. Samantha Paoletti

Dr. Samantha Paoletti

Business Development Manager | CSEM (Landquart, Switzerland)

 

Dr. Adriano Taddeo

Dr. Adriano Taddeo

Senior Research Associate | HES-SO Valais, Diagnostic Systems Research Group (Sion, Switzerland)

 

Dr. Lukas Emmenegger

Dr. Lukas Emmenegger

Head of Department | EMPA (Dübendorf, Switzerland)

 

Confirmed speakers

Dr. Matthias Essenpreis

Dr. Matthias Essenpreis

Chief Technology Officer | Roche Diagnostics (Basel, Switzerland)

Keynote speaker

Abstract

PoC Diagnostics has become key for many patients way to manage their disease. For example, using glucose monitoring in the management of their diabetes or coagulation monitoring to adjust anti-coagulation therapy has become routine for patients and physicians. Historically developed as laboratory tests, the transfer of these solutions into the hands of patients has resulted in improved care and allowed flexible life styles whilst managing the disease.

We are currently seeing the emergence of new solutions for disease management from sensor technologies built into smart phones or wearable devices, many of which will eventually find their way into routing therapy. Combining such approaches with IVD based solutions will create opportunities to improve therapy whilst anchoring decision making in today’s standards of care. Evidence for these new solutions is still scare. However, many approaches are being explored and are already seen to educate patients in their therapy. To find full acceptance, such solutions need to demonstrate clinical safety and efficacy as part of modified treatment protocols. In addition, a seamless integration onto physician’s workflow is required to support broad acceptance and support as part of a therapy. This talk will discuss examples of digitally enabled and patient centric tools and provide a perspective of future developments.

Biography

Matthias joined Roche Diagnostics in 1993 and has held various positions in technology assessment, research and product development. In his current role as Chief Technology Officer, he leads a small team to assess platform technologies for future diagnostics products and provides input for business and strategy planning with insights on technology roadmaps. Previously, he has been responsible for new technology development and innovation within Roche Diabetes Care. Besides new technology platforms for next generation test strips, continuous glucose sensors, minituarized insulin pumps, all of which are currently in product development, he has piloted novel information management solutions for the management of T1 and T2 diabetes. His passion of data driven solutions and business models originated during his time in the US Chief Technology Office (Pleasanton) around the year 2000, where he closely followed the emergence of internet businesses. Matthias holds a PhD in Medical Physics from University College London, U.K. and received his M.Sc. Degree in Physics from Ludwig Maximilians Universität in Munich, Germany. Besides his professional passion for business strategy and innovation management he is very motivated to find better products and solutions for patients and improved outcomes. Outdoor sports (hiking and skiing), art (music, modern and asian art) and cooking are some of his private passions.

 

Dr. Jonathan S. Gootenberg

Dr. Jonathan S. Gootenberg

Fellow at Massachusetts Institute of Technology (MIT) and co-founder of Sherlock Biosciences

Keynote speaker

Abstract

RNA plays important and diverse roles in biology, but molecular tools to manipulate and measure RNA are limited. We demonstrate that RNA-targeting CRISPR effector Cas13 can be engineered for RNA diagnostics and mammalian cell RNA knockdown, binding, and editing. We demonstrate diagnostic applications of Cas13 for rapid and sensitive COVID-19 diagnostics. We also show Cas13 can be heterologously expressed in mammalian and plant cells for targeted knockdown of either reporter or endogenous transcripts, targeted RNA binding for transcript imaging, and programmable RNA editing. We develop engineered Cas13-based RNA editing tools for A-to-I and C-to-U base editing and show applications of these tools for therapeutics. Our results establish CRISPR-Cas13 as a flexible platform for RNA targeting with wide applicability for studying RNA or therapeutics.

Dr. Omar O. Abudayyeh

Dr. Omar O. Abudayyeh

Fellow at Massachusetts Institute of Technology (MIT) and co-founder of Sherlock Biosciences

Keynote speaker

Abstract

RNA plays important and diverse roles in biology, but molecular tools to manipulate and measure RNA are limited. We demonstrate that RNA-targeting CRISPR effector Cas13 can be engineered for RNA diagnostics and mammalian cell RNA knockdown, binding, and editing. We demonstrate diagnostic applications of Cas13 for rapid and sensitive COVID-19 diagnostics. We also show Cas13 can be heterologously expressed in mammalian and plant cells for targeted knockdown of either reporter or endogenous transcripts, targeted RNA binding for transcript imaging, and programmable RNA editing. We develop engineered Cas13-based RNA editing tools for A-to-I and C-to-U base editing and show applications of these tools for therapeutics. Our results establish CRISPR-Cas13 as a flexible platform for RNA targeting with wide applicability for studying RNA or therapeutics.

Dr. Michel Rossier

Dr. Michel Rossier

Head of laboratories and Board member of Institut Central des Hôpitaux (Sion, Switzerland)

 

Dr. Sabine Blum

Dr. Sabine Blum

Associate Doctor - Hematologist | CHUV (Lausanne, Switzerland)

 

Dr. Kavi Ramjeet

Dr. Kavi Ramjeet

Technology Scouting Lead | FIND (Geneva, Switzerland)

 

Dr. Mathias Wipf

Dr. Mathias Wipf

Chief Executive Officer and Co-Founder | MOMM Diagnostics (Basel, Switzerland)

 

Dr. Eberhard Scheuer

Dr. Eberhard Scheuer

Founder | Centiva Health (Zug, Switzerland)

 

Dr. Christian-Benedikt Gerhold

Dr. Christian-Benedikt Gerhold

Head Corporate Research| Bühlmann Laboratories AG (Schönenbuch, CH)

 

Dr. Samantha Paoletti

Dr. Samantha Paoletti

Business Development Manager | CSEM (Landquart, Switzerland)

 

Dr. Adriano Taddeo

Dr. Adriano Taddeo

Senior Research Associate | HES-SO Valais, Diagnostic Systems Research Group (Sion, Switzerland)

 

Dr. Lukas Emmenegger

Dr. Lukas Emmenegger

Head of Department | EMPA (Dübendorf, Switzerland)

 

Our speakers are subject to change and reflect the current situation (20.08.2020). Stay tuned for further information by registering to our newsletter.